Authors’ conclusion: a 4CMenB vaccine is immunogenic against reference strains when administered with routine vaccines at 2, 4 and 6 or at 2, 3 and 4 months of age, producing minimal interference with the response to routine infant vaccinations.
Reviewers’ commentary: randomized controlled trial, to determine both the immunogenicity of a new multi-component serogroup B meningococcal vaccine, as tolerability after its administration with or without routine vaccines; as well as the relationship between adverse effects and the study vaccine. More than 99% of participants had a protector immune response against two of its four components, with mild immunologic interference with some of systematic vaccine antigens (pertussis and serotype 6b pneumococcal). Fever was seen in more than 75% cases, and serious adverse events in 10% of the participants. Its long-term protection and its real clinical effectiveness are unknown.